Health Biotech
Innovative biotech solutions enhancing brain health and delaying aging through advanced carnitine research
About Health Biotech
Haosi Biotech is a pioneering biotechnology company specializing in the research and development of carnitine-based solutions aimed at enhancing brain health and delaying the aging process. The company operates in the healthcare and biotechnology market, serving clients ranging from medical institutions to research organizations. Haosi Biotech's business model revolves around the development, production, and distribution of carnitine products, which are synthesized from lysine and methionine and play a crucial role in brain cell metabolism. The company generates revenue through the sale of these specialized products and through partnerships with healthcare providers and research institutions. In 2020, Haosi Biotech secured hundreds of millions of yuan in Series B financing and was recognized as one of the Top 100 Chinese Innovation and Growth Enterprises and one of the Top 80 Chinese Healthcare Innovation Enterprises. The company also received accolades from the Beijing Municipal Science and Technology Commission for its innovative projects.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2021 | $31M | $122M | Qiming Venture Partners | — |
| SERIES BEquity / VC | Dec 2020 | $14M | $55M | Volcano Capital · Qianhai FOF · Sino-Ocean Group | ↗ |
Growth signals
Latest recorded traffic for Health Biotech is 580 monthly website visits, up 866.7% over the last three months. Health Biotech's team grew 0% over the past year.
Open positions
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Health Biotech in the Changping District ecosystem
The Health Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Qianhai FOF- SGSino-Ocean Group
Volcano Capital
Qiming Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Health Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Health Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.